



A Phase 2 Study of avutometinib (VS-6766) Plus defactinib in Gynecologic Cancers

Study Overview:

The purpose of this research is to test the effectiveness and safety of the study drugs (avutometinib (VS-6766) and defactinib) and see what effects (good and bad) these drugs have on the patients with endometrioid cancer, mucinous ovarian cancer, high-grade serous ovarian cancer, or cervical cancer with RAS, BRAF, or NF1 mutations. Avutometinib and defactinib are both a type of drug called kinase inhibitors. Kinase inhibitors block cancer cell growth.

This is an open-label trial. Every patient will be treated with active study drugs, and their investigator will not be comparing it to a placebo. Avutometinib and defactinib are investigational drugs that have not been approved by the U.S. Food and Drug Administration (FDA).

Study (Protocol) Title: A Phase 2 Study of Avutometinib (VS-6766) (Dual RAF/MEK Inhibitor) Plus Defactinib (FAK Inhibitor) in Recurrent Gynecological Cancers (DURAFK)

Short Title: DURAFK

Study (Protocol) Numbers:

OU Health: DURAFK

Verastem ID: IST-VS-6766-008

Clinical Trial: NCT05787561

Study Drugs or Compounds: avutometinib (VS-6766) and defactinib (VS-6063)

Study Phase: Phase 2

Total Enrollment: 49 patients

Sponsor: University of Oklahoma (OU Health)

Collaborators: Verastem Oncology

Principle Investigator: Christina Washington